Pomalidomide is new drug for Multiple Myeloma

Pomalyst (pomalidomide) has been approved for the treatment of relapsed and/or refractory Multiple Myeloma in patients who have received 2 prior therapies including Revlimid and Velcade and have had disease progression on or within 60 days of completion of their last therapy.